AstraZeneca (Commercial Rights of Atacand and Atacand Plus) is Buildings and Property in United Kingdom that focus on Atacand Plus business. They cover business area such as portfolio, commercial right, Atacand, drug, atacand, a prescription medicine, heart failure, hypertension.
-
Atacand Plus
-
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
England, United Kingdom
Private
portfoliocommercial rightAtacanddrugatacanda prescription medicineheart failurehypertension
* We use standard office opening hours in near AstraZeneca (Commercial Rights of Atacand and Atacand Plus)'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
AstraZeneca (Commercial Rights Of Atacand And Atacand Plus) is Buildings and Property business from United Kingdom that founded in - ( years old in ), AstraZeneca (Commercial Rights of Atacand and Atacand Plus) business is focusing on Atacand Plus.
AstraZeneca (Commercial Rights of Atacand and Atacand Plus) headquarter office and corporate office address is located in 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA England, United Kingdom.
AstraZeneca (Commercial Rights of Atacand and Atacand Plus) was founded in United Kingdom.
In , AstraZeneca (Commercial Rights of Atacand and Atacand Plus) is currently focus on Atacand Plus sector.
Above is snippet of Google Trends for "Atacand Plus" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with AstraZeneca (Commercial Rights of Atacand and Atacand Plus), any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
